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Scavenger receptors: diverse activities and promiscuous binding 
of polyanionic ligands 
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Scavenger receptors are a diverse family of proteins that share 
a common property - the binding of modified lipoprotein - but 
they have recently been shown to recognise a diverse range of 
ligands. Understanding the molecular interaction of receptor- 
ligand binding should provide insight into how scavenger 
receptors contribute to important biological processes. 
Address: Sir William Dunn School of Pathology, University of Oxford, 
South Parks Road, Oxford, OX1 3RE UK. 
Correspondence: Nick Platt 
E-mail: nick.platt@pathology.ox.ac.uk 
Chemistry 81 Bioldgy August 1998,5:R193-R203 
http://biomednet.com/elecref/10745521005R0193 
0 Current Biology Publications ISSN 107475521 
Introduction 
Scavenger receptors are defined by their ability to bind 
modified lipoprotein. In particular, a combination of two 
discoveries - the isolation of new receptors and the iden- 
tification of their broad ligand-binding - has intensified 
research interest in scavenger receptors. Recent reviews 
have concentrated on the general properties and structures 
of scavenger receptors [1,2], and their contributions to 
lipoprotein metabolism [3] and host defense [4,5]. In this 
article we will attempt to relate the biology of scavenger 
receptors to their structure and possible mechanisms of 
their unique ligand-binding properties. A greater knowl- 
edge of the molecular basis of the receptor-ligand interac- 
tion might help us to understand the specific biological 
contributions of scavenger receptors, identify potential 
targets and aid the design of therapeutic molecules. 
Scavenger receptors - an historical perspective 
The family of proteins known as scavenger receptors was 
originally identified by the Nobel laureates Michael 
Brown and Joseph Goldstein [6] in their seminal investiga- 
tions of endocytic uptake of lipoproteins by cells, a key 
aspect of lipid deposition in artery walls during the devel- 
opment of atherosclerotic lesions. They showed that the 
low-density lipoprotein (LDL) receptor was not responsi- 
ble for the accumulation of cholesterol esters, and pro- 
posed and demonstrated the existence of a distinct 
receptor-mediated mechanism. These receptors, originally 
called acetylated LDL receptors, now termed scavenger 
receptors, were capable of endocytosing large quantities of 
chemically modified LDL, culminating in the conversion 
of macrophages into cells packed with esterified choles- 
terol that resemble the foam cells characteristic of the ath- 
erosclerotic plaque [7]. Unlike LDL receptors, scavenger 
receptors are not down-regulated by high intracellular 
levels of cholesterol. Although the involvement of scav- 
enger receptors in the metabolism of modified lipoproteins 
remains the major focus of current research, other develop- 
ments, including the recent isolation of several new recep- 
tors, strongly suggest scavenger receptors play important 
biological roles in addition to their role in vascular disease. 
Scavenger receptors are multifunctional 
The identification of several scavenger receptor genes that 
fall into at least five distinct classes (Figure l), and the 
availability of specific reagents with which to analyse them 
has facilitated studies of the distribution and activities of 
scavenger receptors. All are plasma membrane proteins that 
are expressed on a number of cell types, in particular cells 
of the immune system. Some, such as class A scavenger 
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Structures of the five classes of scavenger receptors. Five classes of 
scavenger receptors have been recognised on the basis of structural 
homologies and ligand-binding properties. Class A are trimeric 
glycoproteins; three members have been identified [1,21. SR-AI and 
SR-All are alternative transcripts from the same gene. They differ from 
each other by the presence of the carboxy-terminal scavenger-receptor 
cysteine-rich domain (black, SRCR) in SR-AI. SR-AI and SR-All have 
four other domains, a cytoplasmic tail (orange), a transmembrane 
domain (blue), an a-helical coiled coil (yellow) and a collagenous 
domain (red) that includes the binding site for acetylated LDL. The third 
member of class A, MARCO, has cytoplasmic, transmembrane and 
spacer domains that are not related to those of SR-AI, but a 
collagenous domain (red) and SRCR (dark blue) that are homologous 
to SR-AI [60]. Class B scavenger receptors [1,8,43] al) have a single 
extracellular domain with a carboxy-terminal region that has conserved 
cysteine residues (green, enclosed c). Class C is currently represented 
by a single molecule, SR-Cl [23] isolated from Drosophila, that is 
composed of multiple domains that include regions homologous to 
vertebrate proteins, including complement control protein (dark purple), 
the MAM (meprinA5 antigen-receptor tyrosine phosphatase k) family 
(pale purple). and a mucin-like domain (pink). Class D and class E 
scavenger receptors are both represented by single species that have 
either a C-type lectin structure (blue, Lox-l [65]) or multiple epidermal 
growth factor (EGF) repeats (pale yellow, endothelial scavenger 
receptor [66]). The protein motif characteristic of each class in 
indicated beneath. Redrawn from [301. 
receptors (SR-As) are essentially restricted in expression to 
a single cell lineage, the macrophages [l]; others, like the 
receptor CD36, are expressed on several cell types, includ- 
ing macrophages, platelets and endothelia [8]. These differ- 
ent patterns of expression are consistent with discrete, and 
sometimes overlapping, biological activities. Experimental 
evidence supports important contributions by scavenger 
receptors to a number of biological processes and we shall 
briefly outline each of these with appropriate examples. 
Scavenger receptors and the endocytosis of 
modified lipoproteins 
By definition, scavenger receptors are able to endocytose 
chemically modified lipoproteins. Typically, this has been 
determined in vitro by measuring either the binding and 
uptake or the degradation of labelled lipoprotein [1,3]. 
Other ligands for scavenger receptors have been identi- 
fied by their ability to inhibit lipoprotein endocytosis. 
The contribution of a specific scavenger receptor to 
lipoprotein endocystosis has been difficult to define in 
ai& because of the presence of a multitude of different 
receptors with apparently overlapping activities. This can 
now be addressed through the recent generation of mice 
that are genetically deficient in certain scavenger receptors. 
Mice that lack type I and type II SR-A (SR-AI and SR-AII) 
were crossed with animals genetically deficient in 
apolipoprotein E, which develop atherosclerotic lesions 
when fed a cholesterol-rich diet. Atherosclerotic plaques 
were about 40% smaller in the double knockout than in the 
single knockout animal [9]. This work confirms the contri- 
bution of SR-AI and SR-AI1 to atherogenesis, but implies 
other receptor mechanisms are involved in the pathology. 
The theme of receptor redundancy orcompensatory mech- 
anisms is supported by analyses of the clearance of modi- 
fied lipoproteins in the SR-A-deficient animal. Although 
Kupffer cells and endothelial cells isolated from the liver of 
the SR-A null mice show reduced endocytosis in vitro, 
there is no difference in the profile of lipoprotein clearance 
in these cells from that of the background strain when oxi- 
dised lipoprotein is injected into the mutant mouse [lo]. It 
is suggested that the failure to observe a phenotype in the 
SR-A null mouse is due to an uncharacterised ligand- 
binding site in the liver. A role for the class B receptor 
SR-BI in high density lipoprotein (HDL) metabolism has 
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been confirmed by the demonstration that mice in which 
the gene for SR-BI has been disrupted have increased con- 
centrations of plasma cholesterol because of a reduction in 
selective cholesterol uptake from the tissues [ll]. 
Studies of human subjects and monocytes and blood- 
derived macrophages in tissue culture suggest that the 
class B receptor CD36 is involved in lipoprotein metabo- 
lism. Expression cloning of molecules able to endocytose 
oxidised LDL resulted in the isolation of CD36 [12]. The 
expression of the receptor is upregulated during the matu- 
ration of monocytes into macrophages [13]; transcriptional 
induction of the gene can occur via activation of the 
nuclear peroxisome-proliferator-activated receptor y 1141. 
Finally monocyte-derived macrophages from patients that 
lack CD36 have reduced, but not absent, endocytosis of 
oxidised LDL in v&o [15]. These studies highlight that 
multiple scavenger receptors are likely to function in the 
uptake of modified lipoproteins in vivo. 
Scavenger receptors as adhesion molecules 
The search for scavenger receptor activities besides endo- 
cytosis has highlighted adhesion as a major function for 
scavenger receptors. This has been deduced largely from 
investigations that have used blocking reagents, such as 
antibodies, that are able to inhibit adhesive interactions. 
Specific antibodies that recognise CD36 are capable of 
preventing the adherence of platelets to collagen and 
thrombospondin-mediated binding of monocytes and 
macrophages to platelets and at various inflammatory sites 
[8]. In addition to the adherence of platelets in the normal 
host, studies using antibodies, supported by work using 
purified CD36 protein and transfected cells, have demon- 
strated that CD36 is the receptor on endothelium to which 
erythrocytes infected with the malarial parasite Phsmod- 
izun falcipamm adhere [8,16]. This sequestration is an 
essential stage in the life cycle of the parasite. 
A similar experimental approach has demonstrated an 
adhesive activity for SR-AI and SR-AII. A monoclonal anti- 
body directed against the receptor can inhibit a component 
of cation-independent adhesion of macrophages on tissue 
culture plastic surfaces in the presence of serum [ 171, which 
has significance for the contribution of SR-A to atherogene- 
sis. SR-A might not only bring about the conversion of 
macrophages into foam cells through endocytic uptake of 
lipoprotein, but might be responsible for the retention of 
circulating cells at the site of the developing plaque. SR-A 
can also mediate adhesion to glucose-modified collagen IV, 
which could explain the accelerated development of vascu- 
lar lesions in diabetics [18]. Other populations of 
macrophages also express SR-A, including activated cells 
[19], and it is possible that the class of receptor is responsi- 
ble for retention of macrophages within tissues and at sites 
of infection, such as in granulomata. Although peritoneal 
macrophages derived from mice lacking SR-A display 
delayed adherence and spreading in culture [9], initial 
investigations have failed to reveal a deficit in macrophage 
adherence Zn vivo (R. Haworth, N.P. and S.G., unpublished 
observations). Again, it is very likely that other receptors 
are involved and it therefore might be necessary to block 
these receptors in order to reveal the role of SR-A. 
Attachment not only brings cells into intimate contact with 
other cells or the extracellular matrix, but signals changes 
in the biological properties of the adherent cell. Platelets 
are activated following CD36-mediated adhesion to colla- 
gen [S]. Interactions with ligands for scavenger receptors 
are known to induce proinflammatory cytokines and 
growth factor production by macrophages, thereby altering 
the microenvironment of the vascular lesion to increase 
the influx of monocytes and promote the proliferation of 
smooth muscle cells [l]. 
SR-A-mediated adhesion is believed to initiate a sequence 
of damaging inflammatory events that contribute to the 
pathology of Alzheimer’s disease. Senile plaques contain 
both microglia that express SR-A and glycated matrix pro- 
teins that are scavenger receptor ligands [ZO]. El Khoury et 
al [Zl] demonstrated that SR-A can mediate the adhesion 
of microglia to ABl-42 amyloid fibrils, which are found in 
plaques, and this stimulates the production of reactive 
oxygen species and cytokines that could damage neigh- 
bouring neurons. Furthermore, because isolated murine 
microglia can endocytose A/3 amyloid aggregates via scav- 
enger receptor(s), the disease process might be accentuated 
through the accumulation of fibrils [ZZ]. 
Scavenger receptors and host defence 
The ability of some scavenger receptors to bind to the 
microbial surface, combined with their expression on rele- 
vant immune cells, suggest that they act as pattern recog- 
nition molecules and contribute to the innate immune 
system [4,5]. This is an apparently ancestral activity 
because specific scavenger receptors have been identified 
in hemocytes of simple animals, such as Drosophila [23]. 
SR-A can also recognise lipopolysaccharide, a component 
of gram-negative’ bacteria, and bind lipoteichoic acid that 
is present on gram-positive bacteria [4,5,24]. Evaluation of 
the SR-A role in host defence has been possible from 
analyses of SR-A-deficient mice. These mice are more sus- 
ceptible to List&z infection than are the wild type [9], and 
isolated macrophages from these animals have a reduced 
capacity to phagocytose Escheticha coli (R. Haworth, N.P. 
and S.G., unpublished observations). Hypersensitivity of 
the SR-A knockout mice to endotoxin challenge con- 
firmed that the receptor is involved in lipid clearance and 
protects against lipopolysaccharide-induced toxic shock 
1241. Other potentially hazardous environmental particu- 
lates, such as asbestos and silica, can also bind to and be 
internalised by scavenger receptors [25,26]. Scavenger 
receptors are therefore important for the functioning of the 
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innate immune system because of their capacity to recog- 
nise ‘non-self’. They might also participate in the acquired 
immune response. SR-AI and SR-AI1 are expressed on 
blood-derived dendritic cells (R. Haworth, N.P. and S.G., 
unpublished observations) and could mediate antigen 
uptake for subsequent processing and presentation to T 
and B cells [27]. Maleylation of certain proteins, which 
converts them to scavenger receptor ligands, enhances 
their ability to stimulate antibody and T cell responses 
through increased antigen uptake [28]. 
Scavenger receptors and the phagocytosis of 
apoptotic cells 
The large number of unwanted host cells that die by 
apoptosis are rapidly phagocytosed by neighbouring cells 
(most frequently macrophages) before they lyse in order 
to prevent tissue damage and inflammation, which is now 
recognised as a vital and conserved stage in programmed 
cell death [29]. Identification of receptors on the phago- 
cyte that are able to mediate recognition and engulfment 
of dying cells has confirmed that many scavenger recep- 
tors have this property [30]. For example, antibody block- 
ing of CD36 inhibits the uptake of apoptotic neutrophils 
by blood-derived human macrophages [31] and transfec- 
tion of this scavenger receptor into cells can confer the 
capability to ingest apoptotic cells [32], as can a Drosophila 
homologue, croguemort. [33]. Thymic macrophages lacking 
SR-A show a 50% reduction in the phagocytosis of apop- 
totic thymocytes in vitro [34]. A characteristic feature of 
cells undergoing apoptosis and aging of erythrocytes is the 
loss of phospholipid asymmetry and the exposure of phos- 
phatidylserine on the outer leaflet of the plasma mem- 
brane [35]. Experimental evidence suggests that exposure 
of phosphatidylserine triggers recognition and uptake by 
certain populations of macrophages [36]. Although the 
identity of the phosphatidylserine receptor on the phago- 
cyte remains unknown, CD36 and SR-BI can bind lipo- 
somes containing anionic phospholipids [37]. Evidence for 
scavenger receptor involvement in cell clearance in viva 
has yet to be demonstrated, however. A failure to clear 
apoptotic cells might have implications for health; 
impaired phagocytosis is now considered to be an impor- 
tant contributor to the development of autoimmune con- 
ditions, such as systemic lupus erythematosis [38]. Other 
modifications of the surface of dying cells, such as oxida- 
tion, might generate ligands for scavenger receptors [39]. 
Scavenger receptors can therefore distinguish ‘altered self 
from ‘self, as well as non-self, which might mean that 
scavenger receptors represent an evolutionary step in the 
development of the immune system. 
Scavenger receptor classes 
During the past three years, several new genes that 
encode molecules that can bind modified lipoproteins 
have been isolated (Figure 1). The ligand-binding proper- 
ties of these proteins suggest that there are at least five 
classes of scavenger receptors (Figure 2). There is no 
sequence motif that is characteristic of all scavenger 
receptors. Receptors of a particular class may share a spe- 
cific protein domain; for example, the macrophage type I 
and II receptors and the molecule MARCO that comprise 
class A all have a collagenous domain that includes the 
binding site for acetylated LDL and possible microbial 
ligands [1,2]. The collectin Clq also has a collagenous 
domain that displays similar ligand-binding properties to 
SR-AI, but because Clq cannot bind acetylated LDL it 
does not qualify as a scavenger receptor [40]. Similarly, 
CD14 is best known as a physiologically important recep- 
tor for lipopolysaccharide (which is a ligand for SR-A) and 
has also been shown recently to bind to apoptotic B cells 
[41], but its potential for binding to modified lipoproteins 
has not yet been reported. SR-AI and MARCO both 
contain a carboxy-terminal domain, the scavenger receptor 
cysteine-rich domain, that is found in many proteins 
which are not scavenger receptors [42]. Whether there is 
also sequence conservation within all classes of scavenger 
receptor will require the identification of additional 
members of those classes that are currently represented by 
only single species (Figure 1). The most intriguing ques- 
tion that the diversity of scavenger receptors begs is how 
do apparently dissimilar receptors bind very similar 
ligands? Clearly data that define the quaternary nature of 
scavenger receptors, for example, the analysis of the crys- 
tallisation of different scavenger receptors combined with 
the same ligand, will be crucial to resolving this problem. 
Scavenger receptors bind a multitude of 
ligands 
Scavenger receptors are defined by their property of 
binding modified, but not native, LDL (with exception of 
SR-BI) [43]. Modifications that include oxidation and 
acetylation convert LDL into a ligand for scavenger recep- 
tors and abolish binding to the LDL receptor. Chemical 
modification of about 15% of the lysine residues of LDL is 
sufficient to convert it into a ligand for SR-AI [44]. The 
feature of scavenger receptors that underlies their contri- 
bution to multiple biological processes is their broad, high- 
affinity ligand-binding activities (Figure 2). This property 
(that of ‘one receptor-many ligands’) sets them apart from 
the vast majority of membrane receptors that can only bind 
a single ligand. They have been described as ‘molecular 
flypaper’ [3]. The range of ligands comprises a diverse 
array of molecules that includes endogenous molecules 
generated during metabolism, such as chemically modified 
lipoproteins, nonphysiological compounds derived from 
the environment, (e.g., asbestos and silica) and molecules 
that are restricted to prokaryotic cells, such as bacterial 
lipopolysaccharide [1,3-S]. Although the precise structural 
requirements for binding to scavenger receptors have not 
been fully determined (see below), all scavenger receptor 
ligands are macromolecular and polyanionic, but the latter 
property alone is insufficient to confer receptor binding, 
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Figure 2 
Scavenger receptors ligands. The ligand- 
binding profiles of members of the five ciasses 
of scavenger receptors are shown. (+) 
indicates the ability of the receptor to 
recognise the molecule, either by direct 
binding or by the ability to inhibit modified 
lipoprotein endocytosis. (-) Indicates when 
the molecule is unable to bind or compete. A 
space indicates the combination has not been 
reported. The binding of acetylated LDL to 
CD36 is controversial and might be 
dependent on species and cell. LDL, low 
density lipoprotein; acLDL, acetylated low 
density lipoprotein; oxLDL, oxidised low 
density lipoprotein; HDL, high density 
lipoprotein; poly(G), polyguanylic acid; poly(l), 
polyinosinic acid; poly(C), polycytidylic acid; 
poly(A), polyadenylic acid; m-BSA, maleylated 
bovine serum albumin; mal-BSA, 
malondialdehyde bovine serum albumin; LPS, 
lipopoylsaccharide; LTA, lipoteichoic acid; E. 
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because many polyanionic molecules are not ligands. It is 
important to stress that although these polyanionic ligands 
can be used to identify scavenger receptors as a group, 
typically they cannot be used to discriminate individual 
members. This can be achieved using more specific 
probes, such as antibodies [ 171. 
It is unlikely that the list of scavenger receptor ligands in 
Figure 2 is complete; for example, the endogenous serum 
ligand required for cation-independent adhesion of 
macrophages by SR-A is still unidentified [17]. Class A 
receptors show ‘nonreciprocal cross-competition’ - that is, 
although one ligand can compete for binding of a second 
ligand, the latter cannot compete for binding by the former 
[ 11. This observation can be explained by several potential 
mechanisms, including the presence of multiple binding 
sites on single receptors or different conformations of the 
receptor that have distinct binding properties, and could 
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have significant bearing on scavenger receptor function in 
biological situations. Because nearly all ligands for SR-A 
have been identified through their inhibition of acetylated 
LDL endocytosis, ligands that bind at sites distinct from 
that for the lipoprotein would be excluded. An alternative 
strategy could employ soluble forms of scavenger receptors 
as an affinity matrix to purify potential ligands. In addition, 
the way in which potential ligands are presented to the 
receptor might be important, albeit as a soluble ligand, as 
high-density ligand on a particle or in the context of the 
surface of a cell. 
Scavenger receptors within a class can also display differ- 
ential ligand binding. The receptor SR-BI differs signifi- 
cantly from other class B scavenger receptors because it 
can bind not only oxidised LDL and acetylated LDL but 
also native LDL and HDL [43]. Expression of mutant 
receptors might be useful for examining these differences 
in ligand binding. Truncated receptors could determine 
the location and extent of the binding site for particular 
ligand(s). Chimeric receptors created by the exchange of 
protein domains could be informative about specificity for 
the binding of multiple ligands. 
Structure-activity studies of SR-A 
Since SR-A types I and II, alternative spliced transcripts 
from a single gene, were the first scavenger receptors to 
be cloned and have their binding properties characterised, 
there have been several reports detailing receptor struc- 
ture and its relationship to biological activity. As shown in 
Figure 1, the predicted protein structures for SR-AI and 
SR-AI1 are trimeric, multi-domain glycoproteins that 
differ only by the presence of an additional cysteine-rich 
domain in the type I molecule. The remainder of the 
extracellular part of each receptor is identical and is com- 
posed of a short spacer domain, an a-helical coiled-coil 
domain necessary for trimer formation and a collagen-like 
domain [45]. When this predicted sequence was obtained 
two questions were raised: which of these extracellular 
domains is responsible for the binding of ligand and what 
is the structural basis that determines the unusual speci- 
ficity? The striking feature of SR-A is the collagenous 
domain, formed by Gly-X-Y amino acid repeats (where X 
and Y are any, but different,’ amino acids), that is highly 
conserved across species and includes a completely con- 
served amino acid sequence with repeated lysine 
residues - Lys-Gly-Gln-Lys-Gly-Glu-Lys-Gly-Ser. 
Truncation mutagenesis of the receptor reveals that the 
carboxy-terminal 22 amino acid region of the collagen 
domain contains the site of acetylated LDL binding 
[46,47] and mutation of Lys337 in bovine SR-A prevents 
all acetylated LDL binding. Interestingly, oxidised LDL 
binding was not completely abolished unless an adjacent 
lysine residue was also substituted, implying differential 
binding requirements. The finding that this cluster of 
positively charged lysine residues is an essential part of 
the ligand-binding site was not entirely unexpected 
because all the ligands for SR-A are negatively charged 
macromolecules (Figure 2). 
The demonstration that synthetic trimerised peptides 
could mimic the core binding site of the bovine receptor 
has facilitated studies of molecular recognition and 
binding [48-SO]. A triple-stranded 18 amino acid peptide, 
but not the single-stranded peptide, formed a collagen- 
like structure and bound acetylated LDL,. binding that 
could be inhibited by maleylated bovine serum albumin 
[48]. A trimeric peptide in which Ly337 was changed to a 
neutral charged alanine residue showed no binding activ- 
ity, as was observed when the same mutation was intro- 
duced into the intact receptor. This small synthetic 
ligand-binding site has been used for biophysical mea- 
surements and molecular modelling of the collagen 
domain. Circular dichroism (CD) spectroscopy measure- 
ments confirmed the predicted triple-helical conformation 
[49] (Figure 3), and its dependence on the strong electro- 
static interactions between three Lys-Glu residues 
(intramolecular ion pairs) and Lys-Gln residues (by 
hydrogen bonding). Unpaired lysine residues that are at 
the outer edge of the helical wheel would be available for 
intermolecular interactions with negatively charged 
ligands (Figure 3b). The stability of the triple helix was 
significantly reduced at a pH < 4.5 and is likely to be 
important for the dissociation of ligand from the receptor 
that occurs in acidic endosomes [50]. A pH-dependent 
change in the conformation of triple-stranded peptides 
derived from the carboxyl terminus of the a-helical coiled- 
coil domain has been described [Sl], which might also be 
involved in ligand release. 
Although studies of these peptides have demonstrated 
that the peptides have properties very similar to those of 
the native receptor, such as the binding of acetylated 
LDL, there is evidence that they do not have all the dis- 
crimination of ligands of the full-length receptor. Pearson 
et ad [SZ] demonstrated that SR-A expressed in Chinese 
hamster ovary (CHO) cells can interact with the polyri- 
bonucleotides poly(1) and poly(G), but not poly(C) or 
poly(A). This is because poly(G) and poly(1) form quadru- 
plexes on whose surface the stereospecific distribution of 
phosphate groups generates a negative charge that is com- 
plementary to the lysine cluster of the collagenous 
domain. Mielewezyk et al. [SO] tested the interactions 
between 30-mer trimeric peptide from the ligand-binding 
site and tetraplex nucleic acids. As expected the peptide 
bound poly(1) (see Figure 3c for proposed model of 
binding), but there was no perturbation of the CD spectra 
with poly(G) or other polyoligonucleotides that are known 
to bind to the complete receptor, indicating that short 
peptide models may not be adequate to explain fully all 
requirements for receptor-ligand interaction. Peptides that 
mimic binding sites could be useful for selecting small 
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Organisation of SR-A type I. (a) Protein domains (I-VI) of the predicted 
structure of SR-A type I [45,46]. TM, transmembrane. (b) Helical wheel 
model of a triple-stranded peptide derived from the collagen-like domain 
that can bind acetylated low-density lipoprotein. The three peptides are 
indicated by yellow, purple and black spheres. The unpaired lysine 
residues are blue; lysine-glutamic acid that form hydrogen bonds are 
red; lysine-glutamine that form ion pairs are green. Single-letter amino- 
acid code is used; glycine residues are marked as G [49]. (c) Model 
(right) for the binding of polyinosinic acid (left, shaded green) to a triple 
peptide (centre, shaded blue) derived from the collagen-like domain [50]. 
Extended (d) and compact (e) forms of soluble human SR-AI and SR- 
All, as seen by rotary shadowing and negative staining [531. Scavenger 
receptor cysteine-rich domain (SRCR), yellow; collagen-like domain, 
green; coiled-coil domain, red; spacer, orange. s-hSR, soluble human 
scavenger receptor. 
molecule agonists or antagonists. Perhaps studies with 
larger fragments of SR-A would identify sequences outside 
of the core ligand-binding domain that affect the interac- 
tion. Techniques such low angle X-ray scattering could be 
used to measure changes in conformation and domain 
organisation of such fragments of receptor complexed with 
ligand. Nuclear magnetic resonance analysis of a receptor 
domain and labelled ligand might be an intermediate, yet 
informative, approach. The definitive data will be 
obtained when SR-A is crystallised and analysed in the 
presence of ligand, but it is acknowledged that attempts to 
produce collagen crystals have so far been unsuccessful. 
The other major drawback with the studies of peptide- 
ligand interactions is the exclusion of the other receptor 
domains that, although they do not bind ligand directly, 
might significantly influence the interaction. Resnick et al. 
[53] have produced quantities of soluble SR-AI and SR- 
AII, sufficient to initiate studies of their covalent structure 
using electron microscopy. Rotary shadowing and negative 
staining of the proteins revealed that the two fibrous 
domains, the a-helical coiled coil and the collagenous 
triple helix, are joined by a flexible hinge with a variable 
angle between the two domains (Figure 3d). This 
extended form is very similar to that predicted from the 
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primary amino acid sequence of the receptors. Compact 
forms were frequently seen (Figure 3e), however, in 
which the collagen domain is bent back on the coiled coil 
with a hinge angle of 0”. This form was dominant at 
neutral pH, establishing the occurrence of this structure 
under physiological conditions and within an integral 
membrane and, subsequently, determining the functional 
relevance of the compact form is an exciting prospect. 
Structure-activity relationships of SR-A ligands 
Although all SR-A ligands are negatively charged macro- 
molecules, this property in itself is not sufficient to deter- 
mine binding. Because SR-A is involved in atherogenesis, 
the minimum modification requirements for the endocyto- 
sis of LDL have been examined. Dose-dependent chemi- 
cal modification of lysine residues by oxidation increased 
lipoprotein degradation by over tenfold [54]. Although 
removal of the positive charge of the lysine residue is 
required, the magnitude of charge change is not the only 
factor involved, because the rate of degradation of succiny- 
lated LDL was not different from acetylated LDL, despite 
a larger net charge, and both were less than that of malon- 
dialdehyde-modified lipoprotein [44]. One possibility is 
that modifications of particular lysine residues on the LDL 
molecule are more important than others. An LDL peptide 
rich in modified lysine residues that can interact with the 
collagenous domain of SR-A might be an alternative 
approach to solving this problem. It is clear that the oxida- 
tion of apoprotein B plays a major role in the binding of 
oxidised LDL to SR-A, but a recent study showing that 
the lipid moiety of oxidised LDL can compete with the 
binding of oxidised red blood cells for mouse macrophages, 
indicates that this component of the lipoprotein might also 
be important for the interaction [SS]. 
We have stated that all scavenger receptor ligands are neg- 
atively charged polyanions, but not all polyanions can bind 
these receptors, presumably because of specific require- 
ments that are currently not well understood. It is very 
likely that particular stereo organisation and density of 
charge are essential. Design and manipulation of model 
ligands has, and will be, of use, but it would, perhaps, be 
more interesting to define physiologically relevant ligands. 
For example, although the adhesion of microglia to sur- 
faces coated with fibrous Apl-42 amyloid peptide could 
be inhibited by poly(1) [Zl], it is unclear if this molecule is 
a polyanion and whether it is the form of the protein that 
is important in viva. 
Identifying scavenger receptor ligands on microorganisms 
is important for defining the role of the receptors in host 
defence. It would help to identify those pathogens with 
which appropriate immune cells bearing scavenger recep- 
tors might be able to interact. SR-A can bind gram-positive 
bacteria, possibly through recognition of lipoteichoic acid 
[56]. Gram-positive bacteria can essentially be divided into 
two subgroups: those in which lipoteichoic acid is the 
major macroamphiphile anchored to the cytoplasmic mem- 
brane and those in which lipoteichoic acid is largely 
replaced by lipoglycans [57]. Greenberg et al. [58] have 
investigated a series of lipoteichoic acid and lipoglycan 
species for their ability to compete with poly(G) for the 
binding of type I bovine SR-A. Many, but not all, lipotei- 
choic acids were able to bind, the strength of binding being 
dependent upon the size of the negative charge of the 
sidechain phosphate groups. The classical lipoteichoic 
acid, from S~up~yloccus u~re~s, showed the highest affinity 
binding, which was increased when the molecule was 
made even more negatively charged. Lipoteichoic acid 
from Enterococcm faecalis and Listeria monoqtogenes, amongst 
others, also bound to SR-A, but those of Streptococcuspneu- 
mania and Clostridium innocuum, which have lipoteichoic 
acid substituted with positive sugar charges (the Forssman 
antigen), failed to bind. The lipoglycan of Bifidoobacterizm. 
bifidium bound as effectively as some lipoteichoic acid 
species, whereas that of Micrococcus Iuteus did not, even 
though it has comparable negative charge. It would seem 
that the distribution as well as the density of charge is criti- 
cal. The latter observation might be of some significance, 
the lipoglycans of Mycobacterizm tubercdosis and M. l’eprae 
have similar sidechain ester substitutions, yet preliminary 
receptor-blocking experiments have suggested that scav- 
enger receptors might be involved in the interaction of 
mycobacteria and human macrophages [59]. The class A 
receptor MARCO has an extended collagen-like domain 
and can bind E. coli and S. uureus [60]; it would be interest- 
ing to compare the breadth of lipoteichoic acid and lipogly- 
can binding with that of SR-AI and SR-AII. That certain 
lipoteichoic acid species and lipoglycans are SR-A ligands 
suggests that soluble receptor or small molecules that 
mimic the collagenous domain might provide effective 
protection against septic shock. 
Structure-activity relationships of CD36 
Human CD36 has been shown to be an adhesion receptor 
for thrombospondin, type I and IV collagen and for 
malaria-infected erythrocytes [8], and be involved in the 
endocytosis of long-chain fatty acids, oxidised lipoproteins 
and anionic phospholipids [37] and the phagocytosis of 
apoptotic cells 13’21. A series of monoclonal antibodies and 
peptides has been used to investigate whether these 
diverse ligands interact with the same region of the recep- 
tor or whether there are multiple sites. The sites of recep- 
tor-ligand binding were investigated by testing the ability 
of the antibodies to block binding and adhesion [61-631. 
In summary, a single domain that extends from amino 
acids 155-183 mediates the interactions with throm- 
bospondin, oxidised LDL and apoptotic neutrophils. 
Chimeric receptors, created by swopping regions between 
human and murine CD36 and receptor-derived peptides 
confirmed the antibody results, but revealed species 
specificity. For both oxidised LDL endocytosis and 
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Figure 4 















Sequence homologies that identify the CLESH-1 (036, LIMPII, emp, 
SR-BI Homology sequence 1) motif amongst CD36-related proteins. 
hu, human; r, rat; m, mouse; ha, hamster; d, Drosophila; ce, 
C. elegans. Regions.of homology are shaded in blue, green and pink. 
Redrawn from [64]. 
human neutrophil ingestion, replacement of human 
155-183 with the murine counterpart (which differs only 
by two amino acids) significantly reduced both lipoprotein 
binding and cell phagocytosis [62,63]. The binding of 
thrombospodin to CD36 has been shown to be a stepwise, 
conformation-dependent event and this might be true for 
the other ligands. Crombie and Silverstein [64] identified 
a region in the mammalian molecule lysosomal integral 
membrane protein II (LIMPII) that is structurally related 
to the 155-183 binding domain of CD36, which also 
bound thrombospondin. Using the consensus sequence 
between these two molecules for database searching, they 
found 14 proteins related to CD36 that contain the 
CLESH-1 (CD36, LIMPII, emp, SR-BI homology 
sequence 1) motif (Figure 4). This offers the prospect to 
study the structure-properties of this domain across 
species and investigate its evolution. 
Concluding remarks 
Studies of scavenger receptors essentially began with 
investigations of a clinical pathology. An ongoing period of 
receptor isolation, determination of structure and proper- 
ties has followed, providing the opportunity to exploit 
these approaches, not only for beneficial therapy for 
health conditions in which scavenger receptors are 
involved, but also to understand their many biological con- 
tributions. Several areas will require further examination, 
however. Our understanding of the molecular criteria that 
define a scavenger receptor ligand remains inadequate 
and we certainly cannot predict which molecules will or 
will not bind. The nature and extent of the chemical alter- 
ations that induce ligand formation and whether proteins 
or lipids are of more or equal importance need to be more 
fully explored. It is likely that in the complex situations in 
which scavenger receptor-ligand interactions occur (such 
as on the surface of apoptotic cells or the extracellular 
matrix), there will be a number of ligands that might 
sequentially bind to allow for a more complex biological 
outcome. Finally, which characteristics of ligand-receptor 
interactions mediate different responses of scavenger 
receptor positive cells, be they adhesion, endocytosis or 
phagocytosis, awaits investigation. 
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